The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCAR-T 2019 | Day 2 round up: targeting AML, progress in myeloma and allogeneic CAR-Ts
John Gribben, MD, DSc , FRCPath, FMed Sci, Barts Cancer Institute, London, UK, is joined by Saar Gill, MD, PhD, University of Pennsylvania, Philadelphia, PA, and David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, to share their highlights from day 2 of the 1st International Workshop on CAR-T (iwCAR-T), held in Miami, FL. The speakers discuss difficulties in targeting acute myeloid leukemia (AML), CAR T-cell therapy in multiple myeloma and clinical trial regulations in China. Allogeneic CAR-Ts are also touched upon.
